LON:GDR

genedrive Interim Earnings Results & Report

genedrive logo
GBX 0.84 -0.07 (-7.22%)
As of 11/20/2026 12:25 PM Eastern

genedrive reported Interim earnings on March 27, 2025. The company reported EPS of -GBX 0.40.

Earnings Announcement Details

Quarter
Interim
Report Date

genedrive EPS Results

Actual EPS
-GBX 0.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

genedrive Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

genedrive Interim Earnings FAQ

genedrive (LON:GDR) reported earnings of -GBX 0.40 per share for Interim. The report was announced on Thursday, March 27, 2025.

genedrive Earnings Headlines

genedrive (LON:GDR) Shares Down 1.3% - Here's Why
Genedrive’s rapid genetic test highlighted by NIHR
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Welsh hospitals extend routine MT-RNR1 testing
See More genedrive Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like genedrive? Sign up for Earnings360's daily newsletter to receive timely earnings updates on genedrive and other key companies, straight to your email.

About genedrive

genedrive (LON:GDR) is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

View genedrive Profile